Comparison of Baseline Characteristics by Primary End Point

Slides:

Advertisements

Similar presentations

Description of Each Study in the Cross Trial Safety Analysis Solomon SD, et al. Circulation 2008 [Epub Mar 31]

Advertisements

TNT: Study Design Treating to New Targets 2 5 years 10,001 Patients Clinically evident CHD LDL-C 130  250 mg/dL following up to 8-week washout and 8-week.

The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:

Cholesterol quintile (mg/dL)

Slide Source: Lipids Online Slide Library Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) 5804 patients aged 70–82.

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

(N=488) Simvastatin in Patients With Prior Cerebrovascular Disease: HPS *29% RRR, p=0.001 Heart Protection Study Collaborative Group. Lancet. 2004;363:

HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.

Pravastatin in Elderly Individuals at Risk of Vascular Disease Presented at Late Breaking Clinical Trials AHA 2002 PROSPER.

The Prospective Pravastatin Pooling Project L I P I D CARECARE PPP Project Investigators Am J Cardiol 1995; 76:899–905.

Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.

WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.

Baseline Characteristics of Cases, Controls, and Entire VA-HIT Population James D. Otvos, et al, Circulation 2006;113:

Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.

The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:

C-1 Efficacy of the Combination: Meta-Analyses Donald A. Berry, Ph.D. Frank T. McGraw Memorial Chair of Cancer Research University of Texas M.D. Anderson.

Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Over Time Additional Risk Factors Can Progress: Effect of Cholesterol and BP on CHD Risk in MRFIT Trial

Methods and Statistical analysis. A brief presentation. Markos Kashiouris, M.D.

Christopher P. Cannon, M. D. , Eugene Braunwald, M. D. , Carolyn H

Copyright © 2012 American Medical Association. All rights reserved.

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis Stavros Stavrakis, MD The American Journal.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study

Table 1. Baseline Characteristics of the 36,636 Study Subjects

LEADER trial: Primary Outcome

Volume 385, Issue 9985, Pages (June 2015)

All-cause mortality by treatment group

Pravastatin in Elderly Individuals at Risk of Vascular Disease

Comparison of baseline characteristics in participants who subsequently had an incident cardiovascular event or new-onset diabetes in the Prospective.

Target Blood Pressure for Treatment of Isolated Systolic Hypertension in the Elderly by Toshio Ogihara, Takao Saruta, Hiromi Rakugi, Hiroaki Matsuoka,

TNT: Baseline and final LDL cholesterol levels

SAVE: Risk of total mortality associated with reduced kidney function

Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease Sripal Bangalore, MD, MHA, Rana Fayyad, PhD,

Baseline characteristics of patients

The Hypertension in the Very Elderly Trial (HYVET)

Trial profile John A Dormandy et al. Lancet 2005;366:

ASCOT-BPLA: Primary and secondary end points

Prospective evaluation of the relationship between C-reactive protein, D-dimer and progression of peripheral arterial disease Scott E. Musicant, MD,

Diabetes Journal Club March 17, 2011

Fung TT, et al. Circulation 2009;119:

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Volume 9, Issue 9, Pages (September 2010)

Potential mechanisms whereby statins may reduce the risk of stroke

Volume 385, Issue 9985, Pages (June 2015)

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Enrollment and Outcomes

Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:

Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,

Baseline Characteristics by Tertiles of Homocysteine

Baseline Characteristics of the Subjects

Baseline Characteristics According to Sex

MATCH Results: Implications for the Internist

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Kaplan-Meier curves showing the time in months to the first inappropriate shock from the start of remote monitoring in primary and secondary prevention.

Baseline Characteristics by hs-CRP

Characteristics of included studies

PROSPER: trial design

Baseline characteristics of the 1,842 men without coronary heart disease and the 230 men with a first coronary heart disease event during the 13-year.

Simvastatin in Patients With Prior Cerebrovascular Disease: HPS

Cumulative incidence of cardiovascular events according to medication group in participants of the 4D study with an LDL-C in its fourth quartile at baseline.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Jeffrey J. Teuteberg et al. JCHF 2015;3:

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

FIELD: Primary outcome

Prasugrel versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Hazard ratios, with 95% confidence intervals as floating absolute risks, as estimate of association between category of updated mean haemoglobin A1c concentration.

Prasugrel and ticagrelor versus clopidogrel; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial.

Presentation transcript:

Comparison of Baseline Characteristics by Primary End Point Naveed Sattar, et al. Circulation 2007;115:981-989

Pearson Correlations Between Continuous Baseline Characteristics and Log CRP Naveed Sattar, et al. Circulation 2007;115:981-989

Relationship Between Categorical Baseline Characteristics and Log CRP Naveed Sattar, et al. Circulation 2007;115:981-989

Kaplan-Meier curves of risk of primary end point (definite or suspect death from CHD, nonfatal myocardial infarction, and fatal or nonfatal stroke) by tertile of baseline CRP In subjects with history of vascular disease (secondary prevention) In all subjects Note that the y axis has a different scale in each figure In subjects without history of vascular disease (primary prevention) Naveed Sattar, et al. Circulation 2007;115:981-989

Numbers of Events and Hazard Ratios (95% CIs) for Tertiles of CRP for Primary End Point in Entire Cohort and Separated by History of Vascular Disease (Primary/Secondary Prevention) and for Secondary and Tertiary End Points in Entire Cohort Naveed Sattar, et al. Circulation 2007;115:981-989

Pravastatin Treatment Effect by Tertile of Baseline CRP Naveed Sattar, et al. Circulation 2007;115:981-989

C Statistic for Multivariate Models Including Only Subjects With No History of Vascular Disease in the Placebo Group Naveed Sattar, et al. Circulation 2007;115:981-989